AI Article Synopsis
- * A rare case is presented involving a 56-year-old man with paratesticular lesions, which were linked to an undescended testicle and an incidental nodule near the umbilicus.
- * After thorough medical examinations, he was diagnosed with a metastatic midgut neuroendocrine tumor, highlighting the complexity of such tumors and their varied presentations.
Article Abstract
Neuroendocrine tumors are malignant neoplasms arising from neuroendocrine cells. These are increasingly recognized with rising incidence and encompass a diverse range of phenotypes. The large majority of these originate in the gastrointestinal tract however primary neuroendocrine tumors have also been reported to arise in a variety of organs such as lung, breast, prostate, and skin. Primary malignant paratesticular masses are often sarcomatous in origin and metastatic spread to the paratesticular region or scrotum is exceedingly rare. We report a fascinating case of a 56-year-old male who had an unusual initial presentation of paratesticular lesions on a background of an undescended testicle and an incidental umbilical nodule. After a combination of radiological and histopathological investigations, he was diagnosed with metastatic midgut neuroendocrine tumor.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11357829 | PMC |
| http://dx.doi.org/10.1016/j.radcr.2024.07.032 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Azadirachtin disrupts ecdysone signaling and alters sand fly immunity.
Parasit Vectors
December 2024
Department of Parasitology, Faculty of Science, Charles University, Prague, Czech Republic.
Background: Leishmaniasis is a group of neglected vector-borne diseases transmitted by phlebotomine sand flies. Leishmania parasites must overcome various defenses in the sand fly midgut, including the insects's immune response. Insect immunity is regulated by the ecdysone hormone, which binds to its nuclear receptor (EcR) and activates the transcription of genes involved in insect immunity.
View Article and Find Full Text PDFGut microbial and functional alterations lead to metagenomic signatures for midgut neuroendocrine tumor patients and for carcinoid syndrome.
Endocr Relat Cancer
December 2024
J Hofland, Internal Medicine, Erasmus MC, Rotterdam, Netherlands.
Article Synopsis
- - Midgut neuroendocrine tumors (NET) are linked to enterochromaffin cells and have shown a unique fecal microbial signature in patients, indicating an altered gut microbiome compared to healthy controls.
- - A study involving sequencing of fecal samples from 60 NET patients and 20 matched controls revealed specific differences in microbial communities, with 16 species and 18 pathways significantly varying between groups, yet no notable differences in microbial composition were found between patients with and without carcinoid syndrome (CS).
- - The research identifies potential microbial signatures that could serve as biomarkers for diagnosing midgut NET and distinguishing between patients with and without CS, with high accuracy in predicting presence based on microbial pathways and species.
SUNLAND: a randomized, double-blinded phase II GERCOR trial of sunitinib versus placebo and lanreotide in patients with advanced progressive midgut neuroendocrine tumors.
Ther Adv Med Oncol
November 2024
Hôpital Edouard Herriot, Lyon, France.
Background: Sunitinib, a multitarget tyrosine kinase inhibitor, showed encouraging antitumor activity and manageable toxicity in patients with advanced midgut neuroendocrine tumors (NETs) in earlier results from phase I and II trials.
Patients And Methods: In this phase II trial, patients with a nonresectable grade 1 or 2 midgut progressive NET and Eastern Cooperative Oncology Group performance status 0-1 were randomly assigned 1:1 to receive 37.5 mg sunitinib or a placebo, combined with 120 mg lanreotide autogel every 28 days.
Clinicopathological and epigenetic differences between primary neuroendocrine tumors and neuroendocrine metastases in the ovary.
J Pathol Clin Res
November 2024
ENETS Center of Excellence, Section of Endocrinology, Department of Internal Medicine, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands.
Article Synopsis
- Current research lacks clarity in distinguishing between primary ovarian neuroendocrine tumors (PON) and neuroendocrine ovarian metastases (NOM), prompting a study of patient data spanning 1991 to 2023, which identified 71 NOM and 17 PON cases.
- Analysis revealed that PON tumors are usually unilateral, often found in teratomas, while NOM are predominantly bilateral and not associated with teratomas.
- The findings suggest a need for different treatment approaches; unilateral PON within teratomas should be treated as PON, while PON without teratoma components show similarities to midgut NET metastases, requiring thorough imaging to check for hidden midgut NET.
Neuroendocrine tumours and pregnancy: Real-world data from an European Neuroendocrine Tumour Centre of Excellence.
J Neuroendocrinol
November 2024
Neuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free Hospital, London, UK.
Neuroendocrine neoplasms (NENs) arise from the diffuse endocrine system and have been considered to be rare. However, the incidence and prevalence of these tumours have increased in recent years, and they are being seen in younger patients including women in the reproductive age group. Due to the paucity of data, diagnostic and therapeutic strategies in managing such tumours during pregnancy can be challenging to both treating physicians and patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!